Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0PLPNX
ADC Name
SGN-ALPV
Synonyms
SGN-ALPV; SGN ALPV; SGNALPV
   Click to Show/Hide
Organization
Seagen Inc.
Drug Status
Phase 1 (Terminated)
Indication
In total 1 Indication(s)
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
4
Antibody Name
h12F3
  Antibody Info 
Antigen Name
Alkaline phosphatase, germ cell type (ALPG); Alkaline phosphatase, placental type (ALPP)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Undisclosed
Combination Type
vedotin
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05229900
Phase 1
A phase 1 study of SGN-ALPV in advanced solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05229900  Clinical Status Phase 1
Clinical Description A phase 1 study of SGN-ALPV in advanced solid tumors.
References
Ref 1 A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors